Genetic variations associated with telomere length predict the risk of recurrence of non‐oropharyngeal head and neck squamous cell carcinoma-Reference-Cited by-同舟云学术

Genetic variations associated with telomere length predict the risk of recurrence of non‐oropharyngeal head and neck squamous cell carcinoma

Published:2024-06-05 Issue:9 Volume:63 Page:1722-1737
ISSN:0899-1987
Container-title:Molecular Carcinogenesis
language:en
Short-container-title:Molecular Carcinogenesis

Author:

Sun Peng¹²,Gu Kyle J.²³,Zheng Guibin²⁴,Sikora Andrew G.²,Li Chao²⁵,Zafereo Mark²,Wei Peng⁶,Wu Jia⁷,Shete Sanjay⁸,Liu Jisheng¹,Li Guojun²^ORCID

Affiliation:

1. Department of Otolaryngology The First Affiliated Hospital of Soochow University Suzhou Jiangsu China

2. Department of Head and Neck Surgery The University of Texas MD Anderson Cancer Center Houston Texas USA

3. Texas Tech University Health Sciences Center School of Medicine Lubbock Texas USA

4. Department of Thyroid Surgery Yantai Yuhuangding Hospital, Qingdao University Yantai Shandong China

5. Department of Head and Neck Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center Affiliated Cancer Hospital of University of Electronic Science and Technology of China Chengdu China

6. Department of Biostatistics The University of Texas MD Anderson Cancer Center Houston Texas USA

7. Department of Imaging Physics The University of Texas MD Anderson Cancer Center Houston Texas USA

8. Department of Epidemiology The University of Texas MD Anderson Cancer Center Houston Texas USA

Abstract

AbstractGenetic factors underlying lymphocyte telomere length (LTL) may provide insights into genomic stability and integrity, with direct links to susceptibility to cancer recurrence. Polymorphisms in telomere‐associated genes are strongly associated with LTL and cancer risk, while few large studies have explored the associations between LTL‐related polymorphisms and recurrence risk of non‐oropharyngeal head and neck squamous cell carcinoma (non‐OPHNSCC). Totally 1403 non‐OPHNSCC patients were recruited and genotyped for 16 LTL‐related polymorphisms identified by genome‐wide association studies. Univariate and multivariate analyzes were performed to evaluate associations between the polymorphisms and non‐OPHNSCC recurrence risk. Patients carrying rs755017 GA/GG, rs2487999 TC/TT, rs2736108 TC/TT, or rs6772228 AT/AA genotypes exhibited shorter DFS than those with the rs755017 AA, rs2487999 CC, rs2736108 CC, or s6772228 TT genotypes, respectively (all log‐rank p < 0.05). Multivariable analysis confirmed an increased risk of recurrence for patients carrying rs755017 GA/GG, rs2487999 TC/TT, rs2736108 TC/TT, or rs6772228 AT/AA genotypes (adjusted hazard ratio [aHR]: 1.66, 95% confidence interval [CI]: 1.32–2.07; aHR: 1.77, 95% CI: 1.41–2.23; aHR: 1.56, 95% CI: 1.22–1.99; aHR: 1.52, 95% CI: 1.20–1.93, respectively). Further stratified analysis revealed stronger associations between these genotypes and recurrence risk in ever‐smokers and patients undergoing chemoradiotherapy. The similar but particularly pronounced results were observed for the combined risk genotypes of the four significant polymorphisms. This is the first large study on non‐OPHNSCC patients showing that LTL‐related polymorphisms may modify risk of non‐OPHNSCC recurrence individually and jointly, particularly when analyzed in the context of smoking status and personized treatment. Larger studies are needed to validate these results.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mc.23768

Reference68 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Lessons learned from the INHANCE consortium: An overview of recent results on head and neck cancer

3. Association between Cigarette Smoking and Mutation of the p53 Gene in Squamous-Cell Carcinoma of the Head and Neck

4. Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522

5. TP53Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response